Byetta LAR Will Become Decision Resources' New Clinical Gold Standard In 2013 For The Treatment Of Type 2 Diabetes
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Amylin/Eli Lilly/Alkermes' Byetta LAR earns Decision Resources' proprietary clinical gold standard status in 2013 for the treatment of type 2 diabetes following its approval for the indication in 2010. Byetta LAR has competitive advantages over currently available and emerging drugs in efficacy and delivery. "Byetta LAR improves on our current gold standard, Amylin/Eli Lilly's Byetta, by offering superior glucose-lowering and weight-loss efficacy with a more convenient dosing schedule (once-weekly versus twice-daily injections), " stated Decision Resources' Analyst Christine Helliwell, Ph.
Clinical and basic science researchers from around the world will convene in Hong Kong from January 28 to 30 for the First International Congress on Abdominal Obesity: "Bridging the Gap between Cardiology and Diabetology." The congress, sponsored by the International Chair on Cardiometabolic Risk (ICCR), is the first-ever specialized forum for sharing new insights and evidence about abdominal obesity and its clinical and public health implications. The congress will feature panels of world-renown experts in cardiology, diabetology, lipidology, endocrinology and metabolism, obesity and nutrition, who will examine and discuss novel approaches, and share scientific and clinical data to benefit healthcare professionals, clinicians and scientists in their fight against the worldwide epidemic of abdominal obesity, diabetes, and cardiovascular disease.
Diabetes Research: New Way To Grow Embryonic Stem Cells Holds Promise Of Dramatic Reduction In Animal Use
A new method of priming early embryos to form embryonic stem (ES) cells has allowed ES cells to be derived from mice used in diabetes research for the first time. This could dramatically reduce the number of animals used to study the genetic basis of type 1 diabetes and has the potential to do the same for mouse models of other diseases too. Understanding the genetic basis of type 1 diabetes is an important area of research. Researchers often use a strain of mouse, known as the non-obese diabetic (NOD) mouse, which spontaneously develops type 1 diabetes. Previously, it was impossible to generate ES cells from NOD mice, so the only way to study a gene of interest was to breed the NOD mouse with a strain of mouse that could be genetically modified.
We are looking for more media volunteers to help us raise awareness of diabetes. A media volunteer is someone who is willing to be interviewed by a journalist. When there is a diabetes news story in the papers or on TV or radio, the story often includes an interview with a person with diabetes. The media likes to have a 'human face' to the story, somebody who the audience can relate to. Making research relevant For example, if there is a news story about a research breakthrough, a media volunteer can show what relevance the research may offer to people with diabetes, instead of the story just being about scientific facts and figures. Please get in touch If you are interested, please contact the Media Relations team on 020 7424 1165 or email press@diabetes.
The first ever diabetes audit of 200 NHS hospitals has found that 20 per cent of patients on hospital wards have diabetes - twice the proportion previously estimated. In addition, the audit, which is due to be published later this year, will also show that people with diabetes stay in hospital longer than other patients. Access to specialist advice The Government's diabetes tsar Dr Rowan Hillson, who is leading the audit, wants to see all patients admitted to hospital with diabetes be given access to specialist advice and believes that having diabetes specialist nurses on wards can reduce readmissions of patients with diabetes, as well as drug errors, and length of stay.
Freedom Meditech Presents Data Showing Benefits Of Non-Invasive Diabetes Screening And Glucose Monitoring In The Eye At London Conference
People with diabetes or who are at risk of developing the disease - now estimated at over 400 million globally - could reduce complications, improve quality of life and reduce healthcare costs by using new non-invasive technology to screen for and monitor the illness, according to a presentation by Freedom Meditech at the 6th Annual Diabetes and Diabetic Retinopathy Conference in London, England. "We believe that our proprietary technologies, which non-invasively measure changes in the eye to detect and monitor diabetes, could identify the presence of the disease earlier, and once found, reduce the pain and inconvenience barriers currently required to maintain optimal glycemic control, " said Craig Misrach, President & CEO of Freedom Meditech.